Real-World Treatment Patterns and Outcomes of Zanubrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at University of California Academic Health Centers: A Retrospective Cohort Study.
Fatigue, bruising, and rash were significantly more common in the zanubrutinib cohort, and headache was significantly more common in the acalabrutinib cohort, and trends favored zanubrutinib for both measures.
A. Ayati, Kanika Chandra, Xiao-Liang Wang et al.
· Oncology and Therapy · 0 citations